Victor Ambros and Gary Ruvkun have been jointly awarded the 2024 Nobel Prize in Physiology or Medicine for their groundbreaking discovery of microRNA (miRNA) in 1993 and its role in post-transcriptional gene regulation. Their research has fundamentally changed our understanding of gene expression, shedding light on how small RNA molecules regulate the transcription and translation of genes into proteins, with significant implications for developmental biology and diseases.

Pharmahungary Group has been at the forefront of miRNA type oligonucleotide drug development for ischemic heart diseases such as acute myocardial infarction and heart failure, the leading cause of death globally according to WHO. Our first miRNA patent family’s primary filing date is 2011. This patent covers 3 protectomiRs, i.e. miRNA type oligonucleotide sequences around 2 miRNA mimics and an antagomir) with cardioprotective properties. In 2023 we filed another patent family on a protectomiR identified in a translational porcine model of acute myocardial infarction with validated cardiocytoprotective effect. For more information see our publications:

• Nagy et al, British Journal of Pharmacology, 2024, PMID: 39294819
• Szabados et al. British Journal of Pharmacology, 2024, PMID: 39472767

Pharmahungary Group current objectives for advancing our protectomiR drug candidates:

1. raise EUR 6M to advance two protectomiR drug candidates to large animal proof-of-concept stage
2. find co-development partners with experience in the chemical modifications of protectomiR oligonucleotides and in oligonucleotide delivery systems.

Please contact us for more information and collaboration opportunities: businessdevelopment@pharmahungary.com.